Mga Batayang Estadistika
| CIK | 1010086 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to SIGA Technologies, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 5, 2025 |
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2025 Exhibit 99.1 SIGA Reports Financial Results for Three and Six Months Ended June 30, 2025 • Generated Product Revenues of $79 million for the Three Months Ended June 30 • Awarded Additional Development Funding of $27 million under the BARDA 19C Contract during the Three Months Ended June 30 • Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, August 5, 2025 (GLOBENEWSWIRE) - SIGA Techno |
|
| August 5, 2025 |
Exhibit 3.2 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SIGA TECHNOLOGIES, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware SIGA Technologies, Inc., a Delaware corporation (hereinafter called the “Corporation”), does hereby certify as follows: FIRST: The name of the corporation is SIGA Technologies, Inc. The name under wh |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2025 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 0-2304 |
|
| August 5, 2025 |
(State or other jurisdiction of incorporation or organization) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 5, 2025 SIGA TECHNOLOGIES, INC. |
|
| August 5, 2025 |
Exhibit 10.1 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY "[***]," HAS BEEN OMITTED BECAUSE IT IS BOTH (1) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 12 2. AMENDMENT/MODIFICATION NO. P00019 3. EFFECTIVE DATE See Block 16C 4. REQUISITION/PURCHASE REQ. NO. AS |
|
| June 12, 2025 |
Exhibit 3.1 AMENDED AND RESTATED BY-LAWS OF SIGA TECHNOLOGIES, INC. A DELAWARE CORPORATION As in effect on June 10, 2025 ARTICLE I OFFICES The registered office shall be in the City of Wilmington, County of New Castle, State of Delaware. The Corporation may also have offices at such other places both within and without the State of Delaware as the board of directors (the “Board”) may from time to |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 10, 2025 SIGA TECHNOLOGIES, INC. |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2025 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 0-230 |
|
| May 8, 2025 |
Exhibit 10.1 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY "[***]," HAS BEEN OMITTED BECAUSE IT IS BOTH (1) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 8 2. AMENDMENT/MODIFICATION NO. P00017 3. EFFECTIVE DATE See Block 16C 4. REQUISITION/PURCHASE REQ. NO. ASP |
|
| May 8, 2025 |
SIGA Reports Financial Results for Three Months Ended March 31, 2025 Exhibit 99.1 SIGA Reports Financial Results for Three Months Ended March 31, 2025 • Received $26 Million IV TPOXX Procurement Order from the U.S. Government in March • $94 million in TPOXX Orders (to be Delivered to U.S. Strategic National Stockpile) outstanding as of March 31, 2025 • Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, May 8, 2025 (GLOBENEWSWIRE) - SIGA Technologies, In |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2025 SIGA TECHNOLOGIES, INC. |
|
| May 8, 2025 |
Exhibit 10.2 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY "[***]," HAS BEEN OMITTED BECAUSE IT IS BOTH (1) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 11 2. AMENDMENT/MODIFICATION NO. P00018 3. EFFECTIVE DATE See Block 16C 4. REQUISITION/PURCHASE REQ. NO. AS |
|
| April 28, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy St |
|
| April 18, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| April 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 8, 2025 SIGA TECHNOLOGIES INC (Exact name of registrant as specified in its charter) Delaware 0-23047 13-3864870 (State or other jurisdiction of incorporation or organization) (Commission file number) (I. |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 17, 2025 SIGA TECHNOLOGIES, INC. |
|
| March 11, 2025 |
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2024 Exhibit 99.1 SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2024 • Increased Product Sales to $133 Million in 2024 • Generated Pre-tax Operating Income and Net Income of $70 Million and $59 Million, Respectively, in 2024 • Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, Mar. 11, 2025 (GLOBENEWSWIRE) - SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a co |
|
| March 11, 2025 |
SIGA Technologies, Inc. Insider Trading Compliance Policy and Procedures (as of June 11, 2024) Exhibit 19.1 SIGA Technologies, Inc. Insider Trading Compliance Policy and Procedures (as of June 11, 2024) Federal and state laws prohibit trading in the securities of a company while in possession of material nonpublic information and in breach of a duty of trust or confidence. These laws also prohibit anyone who is aware of material nonpublic information from providing this information to other |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 0-23047 SI |
|
| March 11, 2025 |
Exhibit 10(nn) SIGA TECHNOLOGIES, INC. 2010 STOCK INCENTIVE PLAN (as amended and restated, effective May 23, 2017) ARTICLE I General 1.1 Purpose The purpose of the SIGA Technologies, Inc. 2010 Stock Incentive Plan (the “Plan”) is to establish a flexible vehicle through which SIGA Technologies, Inc., a Delaware corporation (the “Company”), may offer equity-based compensation incentives to eligible |
|
| March 11, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 11, 2025 SIGA TECHNOLOGIES, INC. |
|
| December 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 10, 2024 SIGA TECHNOLOGIES, INC. |
|
| December 13, 2024 |
Exhibit 3.1 AMENDED AND RESTATED BY-LAWS OF SIGA TECHNOLOGIES, INC. A DELAWARE CORPORATION As in effect on December 10, 2024 ARTICLE I OFFICES The registered office shall be in the City of Wilmington, County of New Castle, State of Delaware. The Corporation may also have offices at such other places both within and without the State of Delaware as the board of directors (the “Board”) may from time |
|
| December 10, 2024 |
Interim Results from STOMP Study of SIGA’s Tecovirimat in Treatment of Mpox Announced Exhibit 99.1 Interim Results from STOMP Study of SIGA’s Tecovirimat in Treatment of Mpox Announced ◾ Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpox ◾ Study stopped enrolling patients in all study arms ◾ Results affirm tecovirimat’s strong safety profile ◾ Efficacy in patients with more severe disea |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 10, 2024 SIGA TECHNOLOGIES, INC. |
|
| November 7, 2024 |
Exhibit 10.7 August 30, 2024 Meridian Medical Technologies, LLC 1945 Craig Road St. Louis, MO 63146 USA Re: Letter Amendment to Promotion Agreement To Whom It May Concern: Reference is hereby made to that certain Promotion Agreement, dated as of May 31, 2019 (as amended prior to the date hereof, the “Agreement”), by and between SIGA Technologies, LLC. (“SIGA”) and Meridian Medical Technologies, In |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2024 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 0 |
|
| November 7, 2024 |
Exhibit 10.6 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY "[***]," HAS BEEN OMITTED BECAUSE IT IS BOTH (1) NOT MATERIALAND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT #1 to STATEMENT OF WORK #1 This Amendment #1 to Statement of Work #1 dated October 19, 2020 (this “Amendment #1”), is entered into and effective September 26, 2024 (“Amendment #1 Effect |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2024 SIGA TECHNOLOGIES, INC. |
|
| November 7, 2024 |
EXHIBIT A STATEMENT OF WORK #1 Exhibit 10.5 EXHIBIT A STATEMENT OF WORK #1 This Statement of Work, details the services that Consultant will provide to SIGA. The services under this Statement of Work shall be conducted under and subject to the terms and conditions of the Consulting Agreement between SIGA and Company dated Month Day, Year, hereinafter (“Agreement”). Scope of Services: Tides Group, LLC will develop and lead a gov |
|
| November 7, 2024 |
Exhibit 10.4 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY "[***]," HAS BEEN OMITTED BECAUSE IT IS BOTH (1) NOT MATERIALAND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT #1 CONSULTING AGREEMENT This Amendment #1 to the Consulting Agreement dated October 19, 2020 (this “Amendment”), is entered into and effective September 1, 2022 (“Amendment Effective Da |
|
| November 7, 2024 |
Exhibit 10.3 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY "[***]," HAS BEEN OMITTED BECAUSE IT IS BOTH (1) NOT MATERIALAND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. CONSULTING AGREEMENT with SIGA Technologies, Inc. This Agreement is made and entered into as of the date of date of last signature below (the “Effective Date”), by and between SIGA Technologies, |
|
| November 7, 2024 |
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2024 Exhibit 99.1 SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2024 • Product Revenues for the Three and Nine months Ended September 30, 2024 were $9 million and $53 million, respectively • Received $122 Million of Procurement Orders from the U.S. Government in the Third Quarter • Corporate Update Conference Call Today at 4:30 PM ET NEW YORK - SIGA Technologies, Inc. (SI |
|
| October 4, 2024 |
SECOND AMENDMENT TO THIRD AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 10.2 SECOND AMENDMENT TO THIRD AMENDED AND RESTATED EMPLOYMENT AGREEMENT This amendment to the Third Amended and Restated Employment Agreement (the “Amendment”) is made and entered into on this October 1, 2024, by and between SIGA Technologies, Inc., a Delaware corporation (the “Company”), and Dr. Dennis E. Hruby (the “Executive” and, together with the Company, the “Parties”). WHEREAS, the |
|
| October 4, 2024 |
AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 10.1 AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This amendment to the Amended and Restated Employment Agreement (the “Amendment”) is made and entered into on this October 1, 2024, by and between SIGA Technologies, Inc., a Delaware corporation (the “Company”), and Daniel J. Luckshire (the “Executive” and, together with the Company, the “Parties”). WHEREAS, the Parties previously |
|
| October 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 4, 2024 (October 1, 2024) SIGA TECHNOLOGIES, INC. |
|
| September 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 23, 2024 SIGA TECHNOLOGIES, INC. |
|
| September 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 20, 2024 (September 19, 2024) SIGA TECHNOLOGIES, INC. |
|
| August 15, 2024 |
Topline Results from PALM 007 Study of SIGA'S Tecovirimat in Treatment of Mpox Released Exhibit 99.1 Topline Results from PALM 007 Study of SIGA'S Tecovirimat in Treatment of Mpox Released ◾ Preliminary analysis shows the study did not reach statistical significance on its primary endpoint of tecovirimat being superior to placebo in lesion resolution for all patients ◾ Results suggest tecovirimat provides clinical benefit vs. placebo in two important patient populations: those treate |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 15, 2024 SIGA TECHNOLOGIES, INC. |
|
| August 1, 2024 |
SIGA Technologies, Inc. Restricted Stock Unit Grant Agreement Exhibit 10.2 SIGA Technologies, Inc. Restricted Stock Unit Grant Agreement THIS AGREEMENT, made as of the [●], day of [●], 20, between SIGA Technologies, Inc. (the “Company”) and [NAME] (the “Participant”). WHEREAS, the Company has adopted and maintains the SIGA Technologies, Inc. 2010 Stock Incentive Plan, as amended (the “Plan”), to establish a flexible vehicle through which the Company may offe |
|
| August 1, 2024 |
Exhibit 10.6 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY "[***]," HAS BEEN OMITTED BECAUSE IT IS BOTH (1) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 9 2. AMENDMENT/MODIFICATION NO. P00016 3. EFFECTIVE DATE See Block 16C 4. REQUISITION/PURCHASE REQ. NO. See |
|
| August 1, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 1, 2024 SIGA TECHNOLOGIES, INC. |
|
| August 1, 2024 |
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2024 Exhibit 99.1 SIGA Reports Financial Results for Three and Six Months Ended June 30, 2024 • Generated Product Sales of $21 Million in the Second Quarter, and $45 Million in the Six Months Ended June 30, 2024 • Received $113 Million Procurement Order from U.S. Government for Oral TPOXX in July • Corporate Update Conference Call Today at 4:30 PM ET NEW YORK - SIGA Technologies, Inc. (SIGA) (NASDAQ: S |
|
| August 1, 2024 |
SIGA Technologies, Inc. Stock Option Grant Agreement Exhibit 10.1 SIGA Technologies, Inc. Stock Option Grant Agreement THIS AGREEMENT, made as of the [●], day of [●], 20, between SIGA Technologies, Inc. (the “Company”) and [NAME] (the “Participant”). WHEREAS, the Company has adopted and maintains the SIGA Technologies, Inc. 2010 Stock Incentive Plan, as amended (the “Plan”), to establish a flexible vehicle through which the Company may offer equity- |
|
| August 1, 2024 |
SIGA Technologies, Inc. Performance-Based Restricted Stock Unit Grant Agreement Exhibit 10.3 SIGA Technologies, Inc. Performance-Based Restricted Stock Unit Grant Agreement THIS AGREEMENT, made as of [•], between SIGA Technologies, Inc. (the “Company”) and [NAME] (the “Participant”). WHEREAS, the Company has adopted and maintains the SIGA Technologies, Inc. 2010 Stock Incentive Plan, as amended (the “Plan”), to establish a flexible vehicle through which the Company may offer |
|
| August 1, 2024 |
Exhibit 10.5 INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of [●] by and between SIGA Technologies, Inc., a Delaware corporation (the “Company”), and [NAME], a [director and an officer] of the Company (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering indemnification and advancement. |
|
| August 1, 2024 |
SIGA Technologies, Inc. Restricted Stock Unit Grant Agreement (Directors) Exhibit 10.4 SIGA Technologies, Inc. Restricted Stock Unit Grant Agreement (Directors) THIS AGREEMENT, made as of the [●] day of June 2024, between SIGA Technologies, Inc. (the “Company”), and [NAME] (the “Participant”). WHEREAS, the Company has adopted and maintains the SIGA Technologies, Inc. 2010 Stock Incentive Plan, as amended (the “Plan”), to establish a flexible vehicle through which the Co |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2024 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 0-2304 |
|
| July 19, 2024 |
SIGA Announces U.S. Government Procurement Order of Exhibit 99.1 SIGA Announces U.S. Government Procurement Order of $113 Million for Oral TPOXX® Exercise of Procurement Option under Current Contract Reflects Continuing Action to Enhance Orthopoxvirus Preparedness NEW YORK (GLOBE NEWSWIRE) - SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that the U.S. Department of Health and Human Services |
|
| July 19, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 19, 2024 SIGA TECHNOLOGIES, INC. |
|
| June 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 13, 2024 (June 11, 2024) SIGA TECHNOLOGIES, INC. |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2024 SIGA TECHNOLOGIES, INC. |
|
| May 7, 2024 |
AMENDMENT #1 TO THE PROMOTION AGREEMENT Exhibit 10.3 EXECUTION VERSION AMENDMENT #1 TO THE PROMOTION AGREEMENT This AMENDMENT #1 TO THE PROMOTION AGREEMENT (“Amendment No. 1”) is entered into and made effective as of September 10, 2020 (the “Amendment No. 1 Effective Date”) between SIGA Technologies, Inc., a Delaware corporation, having an address at 31 East 62nd Street, New York, NY 10065 (“SIGA”), and Meridian Medical Technologies, In |
|
| May 7, 2024 |
Exhibit 10.2 EXECUTION VERSION EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of February 26, 2024, between SIGA Technologies, Inc., a Delaware corporation (the “Company”), and Larry Miller (“Executive”). WHEREAS, the Company and Executive desire to enter into an employment agreement providing for Executive to become the General Counsel of the Company and setti |
|
| May 7, 2024 |
Exhibit 10.6 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRATANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT #2 TO THE PROMOTION AGREEMENT This AMENDMENT #2 TO THE PROMOTION AGREEMENT (this “Amendment No. 2”) is entered into as of March 27, 2024, between SIGA TECHNOLOGIES, INC., a Delaware |
|
| May 7, 2024 |
Exhibit 10.5 March 26, 2024 Meridian Medical Technologies, LLC 6350 Stevens Forest Road, Suite 301 Columbia, Maryland 21046 Attention: General Manager Re: Letter Amendment to Promotion Agreement To Whom It May Concern: Reference is hereby made to that certain Promotion Agreement, dated as of May 31, 2019 (as amended by Amendment No. 1, dated as of September 10, 2020, and the Letter Amendment, date |
|
| May 7, 2024 |
Exhibit 10.4 February 28, 2024 Meridian Medical Technologies, LLC 6350 Stevens Forest Road, Suite 301 Columbia, Maryland 21046 Attention: General Manager Re: Letter Amendment to Promotion Agreement To Whom It May Concern: Reference is hereby made to that certain Promotion Agreement, dated as of May 31, 2019 (as amended prior to the date hereof, the “Agreement”), by and between SIGA Technologies, I |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2024 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 0-230 |
|
| May 7, 2024 |
SIGA Reports Financial Results for Three Months Ended March 31, 2024 Exhibit 99.1 SIGA Reports Financial Results for Three Months Ended March 31, 2024 • Generated Product Sales of $24 Million and Pre-tax Operating Income of $11 Million • Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, May 7, 2024 - SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended Marc |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy St |
|
| April 26, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 1, 2024 (March 27, 2024) SIGA TECHNOLOGIES, INC. |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 0-23047 SI |
|
| March 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 12, 2024 SIGA TECHNOLOGIES, INC. |
|
| March 12, 2024 |
Exhibit 10(nnn) CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY "[***]," HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| March 12, 2024 |
SIGA TECHNOLOGIES, INC. CLAWBACK POLICY Exhibit 97.1 SIGA TECHNOLOGIES, INC. CLAWBACK POLICY The Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of SIGA Technologies, Inc. (the “Company”) believes that it is appropriate for the Company to adopt this Clawback Policy (the “Policy”) to be applied to the Executive Officers of the Company and adopts this Policy November 15, 2023 to be effective as of the Effe |
|
| March 12, 2024 |
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2023 Exhibit 99.1 SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2023 • Increased Product Sales to $131 Million in 2023 • Grew Pre-tax Operating Income to $84 Million in 2023 • Declared Today a Special Cash Dividend of $0.60 per Share • Corporate Update Conference Call Today at 4:30 PM ET NEW YORK - SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmac |
|
| March 12, 2024 |
11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS Exhibit 10(mmm) CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY "[***]," HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| January 22, 2024 |
SIGA Announces Appointment of Diem Nguyen, Ph.D., MBA, as New Chief Executive Officer Exhibit 99.1 SIGA Announces Appointment of Diem Nguyen, Ph.D., MBA, as New Chief Executive Officer January 22, 2024 at 7:30 AM EST NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) - SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Diem Nguyen, Ph.D., will join the Company as chief executive officer (CEO), e |
|
| January 22, 2024 |
Exhibit 10.1 EXECUTION VERSION EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of January 19, 2024, between SIGA Technologies, Inc., a Delaware corporation (the “Company”), and Diem Nguyen (“Executive”). WHEREAS, the Company and Executive desire to enter into an employment agreement providing for Executive to become the Chief Executive Officer of the Company set |
|
| January 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 22, 2024 (January 16, 2024) SIGA TECHNOLOGIES, INC. |
|
| January 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 2, 2024 (January 1, 2024) SIGA TECHNOLOGIES, INC. |
|
| January 2, 2024 |
AMENDMENT TO AMENDED & RESTATED TRANSITION AGREEMENT Exhibit 10.1 AMENDMENT TO AMENDED & RESTATED TRANSITION AGREEMENT This amendment to the Amended and Restated Transition Agreement (the “Amendment”) is made and entered into on this January 1, 2024, by and between SIGA Technologies, Inc., a Delaware corporation (the “Company”), and Phillip Louis Gomez, III (the “Executive” and, together with the Company, the “Parties”). WHEREAS, the Parties previou |
|
| November 7, 2023 |
Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of July 26, 2023, between SIGA Technologies, Inc., a Delaware corporation (the “Company”), and Dr. Jay K. Varma, M.D. (“Executive”). WHEREAS, Executive currently serves as a member of the Board of Directors of the Company (the “Board”); WHEREAS, the Company and Executive desire to enter into an employm |
|
| November 7, 2023 |
11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS Exhibit 10.2 AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 2 2. AMENDMENT/MODIFICATION NO. P00024 3. EFFECTIVE DATE See Block 16C 4. REQUISITION/PURCHASE REQ. NO. 5. PROJECT NO. (If applicable) ASPR-22-00229 6. ISSUED BY HHS/OS/ASPR/BARDA 330 Independence Ave., S.W. Room 640-G Washington DC 20201 CODE HHS/OS/ASPR/BARDA 7. ADMINISTERED BY (If other than Item |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2023 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 0 |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2023 SIGA TECHNOLOGIES, INC. |
|
| November 7, 2023 |
Exhibit 99.1 SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2023 - In Third Quarter, SIGA Received U.S. Government Orders for Approximately $113 Million of Oral TPOXX and $25 Million of IV TPOXX® – - In October, Joint Procurement Framework Contract was signed by European Commission with Anticipated Initial Orders by Participating Countries of Approximately $18 Million |
|
| September 6, 2023 |
SIGA Technologies Names Dr. Jay K. Varma as EVP and Chief Medical Officer Exhibit 99.1 SIGA Technologies Names Dr. Jay K. Varma as EVP and Chief Medical Officer NEW YORK, September 6, 2023 (GLOBE NEWSWIRE) - SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Jay K. Varma has joined SIGA as Executive Vice President and Chief Medical Officer (CMO). He will also continue t |
|
| September 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 6, 2023 SIGA TECHNOLOGIES, INC. |
|
| August 8, 2023 |
11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS Exhibit 10.2 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY "[***]," HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 8 2. AMENDMENT/MODIFICATION NO. P00013 3. EFFECTIVE DATE See Block 16C 4. REQUISITION/PURCHASE REQ. NO. See |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 8, 2023 SIGA TECHNOLOGIES, INC. |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2023 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 0-2304 |
|
| August 8, 2023 |
Exhibit 99.1 SIGA Reports Financial Results for Three and Six Months Ended June 30, 2023 - In July, SIGA Received U.S. Government Orders for Approximately $113 Million of Oral TPOXX and $25 Million of IV TPOXX® - - Corporate Update Conference Call Today at 4:30 PM ET August 8, 2023, 4:05 pm ET NEW YORK - SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, toda |
|
| August 8, 2023 |
Exhibit 10.1 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY "[***]," HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Dr. Dennis E. Hruby [***] Dear Dr. Hruby: This letter sets forth a proposal for the amendment of your employment agreement with SIGA Technologies, Inc., dated as of January 22, 2007, as amended |
|
| July 28, 2023 |
EXHIBIT 99.1 SIGA Announces U.S. Government Procurement Orders of Approximately $138 Million for Oral and IV TPOXX® Exercise of Procurement Options of Approximately $113 Million for Oral TPOXX and Approximately $25 Million for IV TPOXX under Current Contract reflects continuing global action to enhance smallpox preparedness NEW YORK, (GLOBE NEWSWIRE) - SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA) |
|
| July 28, 2023 |
AMENDED & RESTATED TRANSITION AGREEMENT EXHIBIT 10.1 AMENDED & RESTATED TRANSITION AGREEMENT THIS AMENDED & RESTATED TRANSITION AGREEMENT (the “Agreement”), dated July 26, 2023, is entered into by SIGA Technologies, Inc., a Delaware corporation (the “Company”), and Phillip Louis Gomez, III (“Executive”). Capitalized terms used and not otherwise defined herein shall have the meaning set forth in the Employment Agreement, dated October 13 |
|
| July 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 26, 2023 SIGA TECHNOLOGIES, INC. |
|
| July 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 27, 2023 SIGA TECHNOLOGIES, INC. |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 13, 2023 SIGA TECHNOLOGIES, INC. |
|
| May 4, 2023 |
Exhibit 99.1 SIGA Reports Financial Results for Three Months Ended March 31, 2023 - Corporate Update Conference Call Today at 4:30 PM ET - May 4, 2023, 4:05 pm ET NEW YORK - SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2023. “First quarter product revenues primarily reflect the sale o |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 4, 2023 SIGA TECHNOLOGIES INC. |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 4, 2023 SIGA TECHNOLOGIES, INC. |
|
| May 4, 2023 |
SIGA Declares Special Cash Dividend of $0.45 Per Share Exhibit 99.1 SIGA Declares Special Cash Dividend of $0.45 Per Share May 4, 2023, 7:30 am ET NEW YORK - SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that the Board of Directors declared a special cash dividend of $0.45 per share on the common stock of the Company. The special cash dividend is payable on June 1, 2023 to shareholders of rec |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2023 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 0-230 |
|
| April 26, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a- |
|
| March 2, 2023 |
Exhibit 99.1 SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2022 - Approximately $71 Million of International Product Sales in 2022 – - Corporate Update Conference Call Today at 4:30 PM ET - March 2, 2023, 4:05 pm ET NEW YORK - SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 2, 2023 SIGA TECHNOLOGIES, INC. |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 0-23047 SI |
|
| February 14, 2023 |
SIGA / SIGA Technologies, Inc. / D. E. SHAW & CO, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm235349-16sc13g.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1) Under the Securities Exchange Act of 1934 SIGA Technologies, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 826917106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the follo |
|
| February 14, 2023 |
EX-99.2 3 tm235349-16ex2.htm EXHIBIT 2 Exhibit 2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned Reporting Persons hereby agrees to the joint filing, along with all other such Reporting Persons, on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common |
|
| February 14, 2023 |
EX-99.1 2 tm235349-16ex1.htm EXHIBIT 1 Exhibit 1 POWER OF ATTORNEY FOR CERTAIN REGULATORY FILINGS INCLUDING CERTAIN FILINGS UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND THE INVESTMENT ADVISERS ACT OF 1940 I, David E. Shaw, hereby make, constitute, and appoint each of: Edward Fishman, Julius Gaudio, Martin Lebwohl, Maximilian Stone, David Sweet, Nathan Thomas, and Eric Wepsic, acting individually, |
|
| January 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 13, 2023 SIGA TECHNOLOGIES, INC. |
|
| January 17, 2023 |
Exhibit 10.1 EXECUTION VERSION TRANSITION AGREEMENT THIS TRANSITION AGREEMENT (the “Agreement”), dated January 13, 2023 is entered into by SIGA Technologies, Inc., a Delaware corporation (the “Company”), and Phillip Louis Gomez, III (“Executive”). Capitalized terms used and not otherwise defined herein shall have the meaning set forth in the Employment Agreement, dated October 13, 2016, by and bet |
|
| January 17, 2023 |
SIGA Technologies Announces Planned Retirement of CEO Phil Gomez in 2023 Exhibit 99.1 SIGA Technologies Announces Planned Retirement of CEO Phil Gomez in 2023 SIGA Board of Directors has initiated search for new CEO; Dr. Gomez expected to remain in position as CEO until the search is completed to support the transition to a new CEO in 2023. NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) - SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical compan |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 10, 2022 SIGA TECHNOLOGIES, INC. |
|
| November 3, 2022 |
11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS Exhibit 10.6 AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 2 2. AMENDMENT/MODIFICATION NO. P00022 3. EFFECTIVE DATE See Block 16C 4. REQUISITION/PURCHASE REQ. NO. OS302885 5. PROJECT NO. (If applicable) 6. ISSUED BY CODE ASPR-BARDA 7. ADMINISTERED BY (If other than Item 6) CODE ASPR-BARDA 200 Independence Ave., S.W. Room 640-G Washington DC 20201 8. NAME AN |
|
| November 3, 2022 |
11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS Exhibit 10.2 AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 2 2. AMENDMENT/MODIFICATION NO. P00010 3. EFFECTIVE DATE See Block 16C 4.REQUISITION/PURCHASE REQ. NO. 5. PROJECT NO. (If applicable) ASPR-21-02282 6. ISSUED BY CODE ASPR-BARDA 7. ADMINISTERED BY (If other than Item 6) CODE ASPR-BARDA 200 Independence Ave., S.W. Room 640-G Washington DC 20201 8. NAM |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 3, 2022 SIGA TECHNOLOGIES, INC. |
|
| November 3, 2022 |
Exhibit 10.4 CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY "[***]," HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 5 2. AMENDMENT/MODIFICATION NO. P00012 3. EFFECTIVE DATE See Block 16C 4. REQUISITION/PURCHASE REQ. NO |
|
| November 3, 2022 |
Exhibit 10.5 CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY "[***]," HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 3 2. AMENDMENT/MODIFICATION NO. P00021 3. EFFECTIVE DATE See Block 16C 4. REQUISITION/PURCHASE REQ. NO |
|
| November 3, 2022 |
Exhibit 99.1 SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2022 - Approximately $61 Million of International Sales in the Third Quarter – - Corporate Update Conference Call Today at 4:30 PM ET November 3, 2022, 4:05 pm ET NEW YORK - SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three |
|
| November 3, 2022 |
Exhibit 10.3 AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 2 2. AMENDMENT/MODIFICATION NO. P00011 3. EFFECTIVE DATE See Block 16C 4. REQUISITION/PURCHASE REQ. NO. 5. PROJECT NO. (If applicable) 6. ISSUED BY CODE ASPR-BARDA 7. ADMINISTERED BY (If other than Item 6) CODE ASPR-BARDA 200 Independence Ave., S.W. Room 640-G Washington DC 20201 8. NAME AND ADDRESS |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2022 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 0 |
|
| November 3, 2022 |
Exhibit 10.1 CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY "[***]," HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 2 2. AMENDMENT/MODIFICATION NO. P00009 3. EFFECTIVE DATE See Block 16C 4. REQUISITION/PURCHASE REQ. NO |
|
| August 9, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 9, 2022 SIGA TECHNOLOGIES, INC. |
|
| August 9, 2022 |
Exhibit 99.1 SIGA Announces BARDA Exercise of Procurement Options Valued at Approximately $26 Million for IV TPOXX? ? IV TPOXX is an Important Option for Those Unable to Swallow ? ? Option to Fund Post-Marketing Field Study for IV TPOXX also Exercised ? NEW YORK, Aug. 9, 2022 (GLOBE NEWSWIRE) - SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announce |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 31, 2022 SIGA TECHNOLOGIES, INC. |
|
| August 4, 2022 |
Exhibit 99.1 SIGA Reports Financial Results for Three and Six Months Ended June 30, 2022 - Approximately $9 Million of Product Sales in the Second Quarter, including First Oral TPOXX? Sale to the U.S. Department of Defense and Approximately $5 Million of International Sales ? - Received Approximately $60 Million of International Orders for Oral TPOXX? Year to Date, from Ten Jurisdictions under New |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2022 Or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 0-2304 |
|
| July 12, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 12, 2022 SIGA TECHNOLOGIES, INC. |
|
| July 12, 2022 |
Exhibit 99.1 SIGA Announces Approximately $28 Million of International Procurement Orders for Oral TPOXX? (Tecovirimat) - Approximately $26 Million of Orders Received from Canada under Existing Procurement Contracts ? - Approximately $2 Million of Orders Received from Two New Jurisdictions - NEW YORK - SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused |
|
| June 24, 2022 |
SIGA / SIGA Technologies, Inc. / D. E. SHAW & CO, L.P. - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 SIGA Technologies, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 826917106 (CUSIP Number) June 14, 2022 (Date of Event Which Requires Filing of this Statement) Check the following box to designate the rule pursuant to which the Schedule i |
|
| June 24, 2022 |
Exhibit 2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned Reporting Persons hereby agrees to the joint filing, along with all other such Reporting Persons, on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common stock, par value $0. |
|
| June 24, 2022 |
EX-99.1 2 tm2219342d1ex1.htm EXHIBIT 1 Exhibit 1 POWER OF ATTORNEY FOR CERTAIN REGULATORY FILINGS INCLUDING CERTAIN FILINGS UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND THE INVESTMENT ADVISERS ACT OF 1940 I, David E. Shaw, hereby make, constitute, and appoint each of: Edward Fishman, Julius Gaudio, Martin Lebwohl, Maximilian Stone, David Sweet, Nathan Thomas, and Eric Wepsic, acting individually, |
|
| June 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 14, 2022 SIGA TECHNOLOGIES, INC. |
|
| June 16, 2022 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SIGA TECHNOLOGIES, INC. Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware The undersigned, Daniel J. Luckshire, certifies that he is the Executive Vice President and Chief Financial Officer of SIGA Technologies, Inc., a corporation organized and existing under the laws of the State of Delaware ( |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2022 Or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 0-230 |
|
| May 5, 2022 |
SIGA Declares Special Dividend of $0.45 Per Share Exhibit 99.1 SIGA Declares Special Dividend of $0.45 Per Share May 5, 2022, 7:30 am ET NEW YORK - SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that the Board of Directors declared a special dividend of $0.45 per share on the common stock of the Company. The special dividend is payable on June 2, 2022 to shareholders of record at the clos |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 5, 2022 SIGA TECHNOLOGIES, INC. |
|
| May 5, 2022 |
Exhibit 99.1 SIGA Reports Financial Results for Three Months Ended March 31, 2022 - First Sale of Intravenous (IV) TPOXX? to U.S. Government under the 19C BARDA Contract ? - Contract with a New International Jurisdiction for an Initial Order of Approximately $3 Million of Oral TPOXX - - Corporate Update Conference Call Today at 4:30 PM ET - May 5, 2022, 4:05 pm ET NEW YORK - SIGA Technologies, Inc |
|
| May 5, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 5, 2022 SIGA TECHNOLOGIES, INC. |
|
| May 5, 2022 |
Exhibit 10.1 CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY "[***]," HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 4 2. AMENDMENT/MODIFICATION NO. P00023 3. EFFECTIVE DATE 01/14/2022 4. REQUISITION/PURCHASE REQ. NO. O |
|
| April 27, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? ? ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only (as permitted |
|
| April 13, 2022 |
PRE 14A 1 ny20002649x1pre14a.htm PRE 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Co |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 18, 2022 SIGA TECHNOLOGIES, INC. |
|
| March 3, 2022 |
11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS Exhibit 10(uu) AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 2 2. AMENDMENT/MODIFICATION NO. P00008 3. EFFECTIVE DATE See Block 16C 4. REQUISITION/PURCHASE REQ. NO. 5. PROJECT NO. (If applicable) ASPR-21-02282 6. ISSUED BY CODE ASPR?BARDA 7. ADMINISTERED BY (If other than Item 6) CODE ASPR-BARDA 200 Independence Ave., S.W. Room 640-G Washington DC 20201 8. |
|
| March 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 3, 2022 SIGA TECHNOLOGIES, INC. |
|
| March 3, 2022 |
11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS Exhibit 10(vv) AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 2 2. AMENDMENT/MODIFICATION NO. P00020 3. EFFECTIVE DATE See Block 16C 4. REQUISITION/PURCHASE REQ. NO. 5. PROJECT NO. (If applicable) 6. ISSUED BY CODE ASPR?BARDA 7. ADMINISTERED BY (If other than Item 6) CODE ASPR-BARDA 200 Independence Ave., S.W. Room 640-G Washington DC 20201 8. NAME AND ADDRE |
|
| March 3, 2022 |
11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS Exhibit 10(ww) AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 2 2. AMENDMENT/MODIFICATION NO. P00022 3. EFFECTIVE DATE See Block 16C 4. REQUISITION/PURCHASE REQ. NO. 5. PROJECT NO. (If applicable) ASPR-20-02608 6. ISSUED BY CODE HHS/OS/ASPR/BARDA 7. ADMINISTERED BY (If other than Item 6) CODE ASPR?BARDA02 HHS/OS/ASPR/BARDA 330 Independence Ave., S.W. Room 64 |
|
| March 3, 2022 |
11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS Exhibit 10(tt) Certain information marked with ?[***]? has been excluded from this exhibit because such information both (i) is not material and (ii) is the type that the registrant treats as private or confidential. |
|
| March 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2021 Or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 0-23047 SI |
|
| March 3, 2022 |
Exhibit 99.1 SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2021 - Approximately $113 Million of U.S. Product Sales in 2021 ? - Approximately $13 Million of International Product Sales in 2021 ? - Corporate Update Conference Call Today at 4:30 PM ET - March 3, 2022, 4:05 pm ET NEW YORK - SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical |
|
| December 15, 2021 |
Exhibit 3.1 AMENDED AND RESTATED BY-LAWS OF SIGA TECHNOLOGIES, INC. A DELAWARE CORPORATION As in effect on December 9, 2021 ARTICLE I OFFICES The registered office shall be in the City of Wilmington, County of New Castle, State of Delaware. The Corporation may also have offices at such other places both within and without the State of Delaware as the board of directors (the ?Board?) may from time |
|
| December 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 9, 2021 SIGA TECHNOLOGIES, INC. |
|
| November 22, 2021 |
SIGA / SIGA Technologies, Inc. / ESOPUS CREEK VALUE SERIES FUND LP - SERIES A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. 2)* SIGA Technologies, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 826917106 (CUSIP Number) Martin Sklar Kleinberg |
|
| November 22, 2021 |
SCHEDULE A Transactions in the Common Stock of the Issuer by Reporting Persons During the Past 60 Days Date Buy/Sell Security Approximate Price Per Share1 Amount of Shares Bought/(Sold) Hutch Master Fund Ltd. 09/20/2021 BUY Common Stock $6.64 2,500 1 Including any brokerage fees |
|
| November 4, 2021 |
Exhibit 99.1 SIGA Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2021 - Up to Approximately $113 Million of Oral TPOXX? Targeted for Delivery to the U.S. Government in the Fourth Quarter - - Approximately $13 Million of International Sales for the First Nine Months of 2021 - - Corporate Update Conference Call Today at 4:30 PM ET November 4, 2021, 4:05 pm ET NEW YOR |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2021 Or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 0 |
|
| November 4, 2021 |
Exhibit 10.1 AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 3 2.AMENDMENT/MODIFICATION NO. P00007 3. EFFECTIVE DATE See Block 16C 4. REQUISITION/PURCHASE REQ. NO. OS281784 5. PROJECT NO. (if applicable) ASPR-21-02282 6. ISSUED BY CODE ASPR-BARDA 7. ADMINISTERED BY (if other than Item 6) CODE ASPR-BARDA 200 Independence Ave., S.W. Room 640-G Washington DC 202 |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 4, 2021 SIGA TECHNOLOGIES, INC. |
|
| September 17, 2021 |
SIGA / SIGA Technologies, Inc. / MacAndrews & Forbes Inc. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 15) SIGA Technologies, Inc. (Name of issuer) Common Stock, par value $0.0001 per share (Title of class of securities) 826917-10-6 (CUSIP number) Shiri Ben-Yishai Executive Vice President and Chief Legal Officer MacAndrews & Forbes Incorporated 31 East 62nd S |
|
| September 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 14, 2021 SIGA TECHNOLOGIES, INC. |
|
| September 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 7, 2021 SIGA TECHNOLOGIES, INC. |
|
| August 17, 2021 |
SIGA / SIGA Technologies, Inc. / ESOPUS CREEK VALUE SERIES FUND LP - SERIES A Activist Investment SC 13D/A 1 siga13da1-081721.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. 1)* SIGA Technologies, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 826917106 (CUSI |
|
| August 17, 2021 |
begin 644 siga13da1-081721.pdf M)5!$1BTQ+C,-,2 P(&]B:@T\/"]4>7!E("]83V)J96-T("]3=6)T>7!E("]) M;6%G92 O3F%M92 O26TQ("]7:61T:" Q-S P("](96EG:'0@,C(P," O3&5N M9W1H(#,X-#,S-B]#;VQO'1H<'" D+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T,O; $,! M"0D)# L,& T-&#(A'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R M,C(R,C(R,C(R,C(R,C(R,C(R,O !$(")@&I ,!(@ "$0$#$0'Q ? ! M!0$! 0$! 0 0(#! 4&!P@)"@OQ "U$ " 0,# @0#!04$! M 7T! @ |
|
| August 5, 2021 |
Exhibit 99.1 SIGA Reports Financial Results for Three and Six Months Ended June 30, 2021 - Approximately $7 Million in International Sales of Oral TPOXX? in the Second Quarter - - Authorization of Additional $50 Million Share Repurchase Program - - Corporate Update Conference Call Today at 4:30 PM ET August 5, 2021, 4:05 pm ET NEW YORK - SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial- |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 5, 2021 SIGA TECHNOLOGIES, INC. |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2021 Or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 0-2304 |
|
| June 17, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 15, 2021 SIGA TECHNOLOGIES, INC. |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 6, 2021 SIGA TECHNOLOGIES, INC. |
|
| May 6, 2021 |
Exhibit 99.1 SIGA Reports Financial Results for Three Months Ended March 31, 2021 - Approximately $3 Million in International Sales of Oral TPOXX? in the First Quarter ? - Approximately $7 Million in International Sales of Oral TPOXX? in April ? - Corporate Update Conference Call Today at 4:30 PM ET May 6, 2021, 4:05 pm ET NEW YORK - SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stag |
|
| May 6, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2021 Or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 0-230 |
|
| April 27, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION ? PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ????Filed by a Party other than the Registrant ??? Check the appropriate box: ?? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by Rule |
|
| March 4, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2020 Or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 0-23047 SI |
|
| March 4, 2021 |
Exhibit 99.1 SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2020 - Approximately 363,000 Courses of Oral TPOXX? Delivered to U.S. Government in 2020 ? - International Contracts for the Purchase of up to Approximately $47 Million of Oral TPOXX? Since April 2020 ? - Corporate Update Conference Call Today at 4:30 PM ET - March 4, 2021, 4:05 pm ET NEW YORK - SIGA Technol |
|
| March 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 4, 2021 SIGA TECHNOLOGIES, INC. |
|
| February 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. )* SIGA Technologies, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 826917106 (CUSIP Number) Martin Sklar Kleinberg, |
|
| February 23, 2021 |
EXHIBIT 99.2 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13D with respect to the Common stock, par value $0.0001 per share, of SIGA Technologies, Inc. dated as of the date hereof is, and any further amendments thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rul |
|
| February 23, 2021 |
SIGA Technologies Proposed Recapitalization February 2021 FOR DISCUSSION PURPOSES ONL Y . |
|
| January 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 20, 2021 SIGA TECHNOLOGIES, INC. |
|
| January 22, 2021 |
THIRD AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 10.1 THIRD AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”), made in New York, New York as of January 20, 2021 (the “Effective Date”), between SIGA Technologies, Inc., a Delaware corporation (the “Company”), and Robin E. Abrams (“Executive”). WHEREAS, the Company and the Executive are parties to that certain Employment Agreement mad |
|
| January 13, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 13, 2021 SIGA TECHNOLOGIES, INC. |
|
| January 13, 2021 |
Exhibit 99.1 SIGA Announces Public Health Agency of Canada Contract Award to Purchase Up To Approximately $33 Million of Oral TPOXX® Second Contract by a Canadian Governmental Agency for the Procurement of Oral TPOXX January 13, 2021 NEW YORK - SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the Pu |
|
| January 4, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 1)* SIGA Technologies, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 826917106 (CUSIP Number) December 31, 2020 (Date |
|
| December 11, 2020 |
THIRD AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 10.1 Execution Version THIRD AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS THIRD AMENDED AND RESTATED AGREEMENT (the "Agreement"), made in New York, New York as of December 10, 2020 between SIGA Technologies, Inc., a Delaware corporation (the "Company"), and Dr. Dennis E. Hruby ("Executive"). WHEREAS, the Company and Executive entered into an Employment Agreement dated January 22, 2007 (t |
|
| December 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 10, 2020 SIGA TECHNOLOGIES INC. |
|
| November 5, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2020 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 0 |
|
| November 5, 2020 |
11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS Exhibit 10.2 AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 4 2. AMENDMENT/MODIFICATION NO. P00019 3. EFFECTIVE DATE See Block 16C 4. REQUISITION/PURCHASE REQ. NO. 5. PROJECT NO. (If applicable) 6. ISSUED BYCODE ASPR-BARDA 7. ADMINISTERED BY (If other than Item 6) CODE ASPR-BARDA 200 Independence Ave., S.W. Room 640-G Washington DC 20201 8. NAME AND ADDRESS |
|
| November 5, 2020 |
11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS Exhibit 10.1 AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF 1 PAGES 4 2. AMENDMENT/MODIFICATION NO. P00021 3. EFFECTIVE DATE See Block 16C 4. REQUISITION/PURCHASE REQ. NO. OS260888 5. PROJECT NO. (if applicable) ASPR-20-02608 6. ISSUED BYCODE HHS/OS/ASPR/BARDA 7. ADMINISTERED BY (if other than item 6) CODE ASPR-BARDA02 HHS/OS/ASPR/BARDA 330 Independence Ave., S.W. R |
|
| November 5, 2020 |
Exhibit 99.1 SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2020 - Third Quarter includes Delivery of Approximately 134,000 Courses of TPOXX® to U.S. Government – - In October, the Public Health Agency of Canada Announced its Intent to Purchase up to 33,300 Courses of Oral TPOXX® – - Corporate Update Conference Call Today at 4:30 PM ET - November 5, 2020, 4:05 pm ET N |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 5, 2020 SIGA TECHNOLOGIES, INC. |
|
| October 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 30, 2020 SIGA TECHNOLOGIES, INC. |
|
| August 6, 2020 |
Exhibit 99.1 SIGA Technologies, Inc. Reports Financial Results for Three and Six Months Ended June 30, 2020 - Second Quarter includes Deliveries to SNS and First International Delivery - - Corporate Update Conference Call Today at 4:30 PM ET - August 6, 2020, 4:05 pm ET NEW YORK - SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health securit |
|
| August 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2020 SIGA TECHNOLOGIES, INC. |
|
| August 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2020 SIGA TECHNOLOGIES, INC. |
|
| August 6, 2020 |
11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS EX-10.1 2 ex194496.htm EXHIBIT 10.1 Exhibit 10.1 Certain portions of this exhibit have been omitted pursuant to Rule 601(b)(10) of Regulation S-K. The omitted information is (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed. Information that has been omitted has been noted in this document with a placeholder identified by the term “{redacted}”. A |
|
| August 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2020 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 0-2304 |
|
| June 26, 2020 |
June 26, 2020 Christine Allen Torney Securities and Exchange Commission Division of Corporation Finance Office of Life Science 100 F Street, N. |
|
| June 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 23, 2020 SIGA TECHNOLOGIES, INC. |
|
| June 18, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 16, 2020 SIGA TECHNOLOGIES, INC. |
|
| June 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive Proxy State |
|
| May 14, 2020 |
SIGAQ / SIGA Technologies, Inc. / Esopus Creek Value Series Fund Lp - Series A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| May 14, 2020 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. )* SIGA Technologies, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 826917106 (CUSIP Number) May 14, 2020 (Date of Ev |
|
| May 6, 2020 |
Exhibit 99.1 SIGA Technologies, Inc. Reports Financial Results for the First Quarter of 2020 - Company Recently Announced Exercise of Contract Options Totaling $101.3 million - - Corporate Update Conference Call Today at 4:30 PM ET - May 6, 2020, 4:05 pm ET NEW YORK - SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, tod |
|
| May 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 6, 2020 SIGA TECHNOLOGIES, INC. |
|
| May 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2020 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 0-230 |
|
| May 6, 2020 |
11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS Exhibit 10.1 Certain portions of this exhibit have been omitted pursuant to Rule 601(b)(10) of Regulation S-K. The omitted information is (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed. Information that has been omitted has been noted in this document with a placeholder identified by the term “{redacted}”. AMENDMENT OF SOLICITATION/MODIFICATIO |
|
| April 29, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 29, 2020 SIGA TECHNOLOGIES, INC. |
|
| April 29, 2020 |
Exhibit 99.1 SIGA Announces BARDA Exercise of Contract Options Valued at $101.3 Million for the Procurement of Oral TPOXX® Deliveries to Maintain National Security Expected to Start in Second Quarter 2020 April 29, 2020 NEW YORK - SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced the exercise of options u |
|
| April 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| March 10, 2020 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 9, 2020 SIGA TECHNOLOGIES, INC. |
|
| March 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 5, 2020 SIGA TECHNOLOGIES, INC. |
|
| March 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 5, 2020 SIGA TECHNOLOGIES, INC. |
|
| March 5, 2020 |
EXHIBIT 4(b) DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 DESCRIPTION OF CAPITAL STOCK The Amended and Restated Certificate of Incorporation (“Certificate of Incorporation”) of SIGA Technologies, Inc. |
|
| March 5, 2020 |
11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS Exhibit 10(rr) Certain portions of this exhibit have been omitted pursuant to Rule 601(b)(10) of Regulation S-K. |
|
| March 5, 2020 |
Exhibit 99.1 SIGA Technologies, Inc. Reports Financial Results for Fiscal Year 2019 - Announces Expectations for Product Delivery to BARDA - - Announces $50 Million Share Repurchase Program - - Corporate Update Conference Call Today at 4:30 PM ET - March 5, 2020, 4:05 pm ET NEW YORK - SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health sec |
|
| March 5, 2020 |
11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS Exhibit 10(ss) Certain portions of this exhibit have been omitted pursuant to Rule 601(b)(10) of Regulation S-K. |
|
| March 5, 2020 |
SIGA / SIGA Technologies, Inc. 10-K - Annual Report - 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2019 Or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 0-23047 SI |
|
| February 25, 2020 |
Please see PDF attached for document reference EX-99.1 2 sigatech13da2-ex993-022420.htm Please see PDF attached for document reference |
|
| February 25, 2020 |
SIGAQ / SIGA Technologies, Inc. / Esopus Creek Value Series Fund Lp - Series A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| February 25, 2020 |
.]V/F1\*"=C.&1,Y[S _IN=,)_)R34 begin 644 sigatech13da2-ex993-022420.pdf M)5!$1BTQ+C8-)>+CS],-"CD@,"!O8FH-/#PO3&EN96%R:7IE9" Q+TP@,3(P M.3@V+T\@,3$O12 Q,38Y,#$O3B Q+U0@,3(P-C@Y+T@@6R U,#0@,30P?S!C&$TNAQM6 C62\U@GEOP0(, #7?A,M#0IE;F1S=')E86T- M96YD;V)J#3$P(# @;V)J#3P\+T%$0D5?1FEL;%-I9VY);F9O/#PO5F5R7!E+T-A=&%L;V<^/@UE;F1O8FH-,3$@,"!O8FH- M/#PO0V]N=&5N=',@,3,@,"!2+T-R;W!";WA;," P(#8Q,B W.3)=+TUE9&EA M0F]X6S @," V,3(@-SDR72]087)E;G |
|
| February 13, 2020 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)1 SIGA Technologies, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 826917106 (CUSIP Number) Martin Sklar, Kleinberg, Kap |
|
| February 13, 2020 |
begin 644 sigatechex99-1.pdf M)5!$1BTQ+C,-,2 P(&]B:@T\/"]4>7!E("]83V)J96-T("]3=6)T>7!E("]) M;6%G92 O3F%M92 O26TQ("]7:61T:" Q-S P("](96EG:'0@,C(P," O3&5N M9W1H(#,V,#0Y-"]#;VQO'1H<'" D+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T,O; $,! M"0D)# L,& T-&#(A'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R M,C(R,C(R,C(R,C(R,C(R,C(R,O !$(")@&I ,!(@ "$0$#$0'Q ? ! M!0$! 0$! 0 0(#! 4&!P@)"@OQ "U$ " 0,# @0#!04$! M 7T! @, |
|
| February 13, 2020 |
EXHIBIT 99.2 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13D with respect to the Common stock, par value $0.0001 per share, of SIGA Technologies, Inc. dated as of the date hereof is, and any further amendments thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rul |
|
| February 13, 2020 |
Please see attached pdf. |
|
| February 13, 2020 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. )1 SIGA Technologies, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 826917106 (CUSIP Number) Martin Sklar, Kleinberg, Kapl |
|
| February 13, 2020 |
SCHEDULE A Transactions in the Common Stock of the Issuer by Reporting Persons During the Past 60 Days Date Buy/Sell Security Approximate Price Per Share1 Amount of Shares Bought/(Sold) Hutch Master Fund Ltd. |
|
| February 13, 2020 |
EXHIBIT 99.2 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13D with respect to the Common stock, par value $0.0001 per share, of SIGA Technologies, Inc. dated as of the date hereof is, and any further amendments thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rul |
|
| January 2, 2020 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 2)* SIGA Technologies, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 826917106 (CUSIP Number) December 31, 2019 (Date |
|
| November 5, 2019 |
SIGA / SIGA Technologies, Inc. 10-Q - Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2019 Or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 0 |
|
| November 5, 2019 |
11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS Exhibit 10.1 AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 5 2. AMENDMENT/MODIFICATION NO P00003 3. EFFECTIVE DATE See Block 16C 4. REQUISITION/PURCHASE REQ NO. OS243619 5. PROJECT NO (If applicable) ASPR-19-03461 6. ISSUED BY CODE ASPR-BARDA 7. ADMINISTERED BY (If other than Item 6) CODE ASPR-BARDA 200 Independence Ave., S.W. Room 640-G Washington DC 20201 |
|
| August 6, 2019 |
Contract No. HHSO100201100023C Modification No. 19 Continuation Sheet Block 14 Page 3 of 4 FUNDS ALLOTTED PRIOR TO MOD #19 $ 36,804,565.90 FUNDS ALLOTTED WITH MOD #19 $ 2,114,660.00 TOTAL FUNDS ALLOTTED TO DATE $ 38,919,225.90 (Changed) CONTRACT EXPIRATION DATE: December 30, 2020 (Unchanged) CLIN 0002 POP 18Feb2018 (Unchanged) CLIN 0003 POP 30Dec2019 (Unchanged) CLIN 0004 POP 30Dec2020 (Unchanged) |
|
| August 6, 2019 |
FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT Exhibit 10.4 FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This FOURTH AMENDMENT (this “Amendment”) dated as of July 24, 2019 in respect of that certain Loan and Security Agreement dated as of September 2, 2016 (as amended by that First Amendment dated as of September 27, 2016, as further amended by that Second Amendment dated as of June 25, 2018, as further amended by that Third Amendment dated |
|
| August 6, 2019 |
SIGA / SIGA Technologies, Inc. 10-Q - Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2019 Or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 0-2304 |
|
| July 2, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 2, 2019 SIGA TECHNOLOGIES, INC. |
|
| June 3, 2019 |
Exhibit 10.1 Certain portions of this exhibit have been omitted pursuant to Rule 601(b)(10) of Regulation S-K. The omitted information is (i) not material and (ii) would likely cause competitive harm to the Company if publicly disclosed. Information that has been omitted has been noted in this document with a placeholder identified by the mark “[***]”. EXECUTION COPY PROMOTION AGREEMENT by and bet |
|
| June 3, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 31, 2019 SIGA TECHNOLOGIES, INC. |
|
| June 3, 2019 |
Exhibit 99.1 SIGA Announces TPOXX® Promotion Agreement with Meridian Medical Technologies, Inc. (A Pfizer Company) for International Markets June 3, 2019, 7:30 am ET NEW YORK - SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has entered into an international promotion agreement with Meridian Med |
|
| May 22, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 21, 2019 SIGA TECHNOLOGIES, INC. |
|
| May 20, 2019 |
Exhibit 99.1 SIGA Announces Exercise of Option for the Purchase of Raw Materials for Oral TPOXX® Manufacturing Totaling $11 Million Raw Materials expected to be used to Support Manufacture of 363,070 Courses of Oral TPOXX May 20, 2019 NEW YORK - SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced the exerci |
|
| May 20, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 17, 2019 SIGA TECHNOLOGIES, INC. |
|
| May 20, 2019 |
11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS Exhibit 10.1 Certain portions of this exhibit have been omitted pursuant to Rule 601(b)(10) of Regulation S-K. The omitted information is (i) not material and (ii) would likely cause competitive harm to the Company if publicly disclosed. Information that has been omitted has been noted in this document with a placeholder identified by the mark “[***]”. AMENDMENT OF SOLICITATION/MODIFICATION OF CON |
|
| May 10, 2019 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 6, 2019 SIGA TECHNOLOGIES, INC. |
|
| May 2, 2019 |
SIGA / SIGA Technologies, Inc. 10-Q Quarterly Report 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2019 Or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 0-230 |
|
| April 29, 2019 |
SIGA / SIGA Technologies, Inc. DEF 14A DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a- |
|
| March 6, 2019 |
SIGA / SIGA Technologies, Inc. 10-K (Annual Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2018 Or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 0-23047 Ta |
|
| March 6, 2019 |
COMMERCIAL MANUFACTURING AGREEMENT COMMERCIAL MANUFACTURING AGREEMENT This COMMERCIAL MANUFACTURING AGREEMENT (this “Agreement”) is entered into effective as of October 1, 2018 (the “Effective Date”), by and between SIGA Technologies, Inc. |
|
| March 6, 2019 |
1. CONTRACT ID CODE PAGE OF PAGES AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1 2 2. AMENDMENT/MODIFICATION NO. 0001 3. EFFECTIVE DATE See Block 16C 4. REQUISITION/PURCHASE REQ. NO. OS235415 5. PROJECT NO. (If applicable) 6. ISSUED BY CODE HHS/OS/ASPR/BARDA 7. ADMINISTERED BY (If other than Item 6) CODE ASPR-BARDAO1 US DEPT OF HEALTH & HUMAN SERVICES ASST SEC OF PREPAREDNESS & RESPONSE ACQ |
|
| February 14, 2019 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* SIGA Technologies, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 826917106 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursu |
|
| February 13, 2019 |
SIGAQ / SIGA Technologies, Inc. / Nantahala Capital Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* SIGA Technologies, Inc. (Name of Issuer) Common Stock, par value $.0001, per share (Title of Class of Securities) 826917106 (CUSIP Number) December 31, 2018 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| November 6, 2018 |
Exhibit 10.7 AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 3 2. AMENDMENT/MODIFICATION NO 0018 3. EFFECTIVE DATE See Block 16C 4. REQUISITION/PURCHASE REQ NO 5. PROJECT NO. (if applicable.), 6. ISSUED BY CODE HHS/OS/ASPR/BARDA 330 Independence Ave., S.W. Room 640-G Washington DC 20201 HHS/OS/ASPR/BARDA 7 ADMINISTERED BY (if other than Item 6) CODE ASPR-BARD |
|
| November 6, 2018 |
Exhibit 10.6 AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 15 2. AMENDMENT/MODIFICATION NO 0017 3. EFFECTIVE DATE See Block 16C 4. REQUISITION/PURCHASE REQ NO 5. PROJECT NO. (if applicable.), 6. ISSUED BY CODE ASPR - BARDA 200 Independence Ave., S.W. Room 640-G Washington DC 20201 ASPR - BARDA 7 ADMINISTERED BY (if other than Item 6) CODE ASPR-BARDA 330 Ind |
|
| November 6, 2018 |
SIGA / SIGA Technologies, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2018 Or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 0 |
|
| November 6, 2018 |
Exhibit 10.5 AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 | 2 2 AMENDMENT/MODIFICATION NO. 0016 3. EFFECTIVE DATE See Block 16C 4. REQUISITION/PURCHASE REQ. NO. OS227396 5. PROJECT NO. (If applicable) 6. ISSUED BY CODE ASPR-BARDA 7. ADMINISTERED BY (If other than Item 6) CODE ASPR-BARDA02 ASPR-BARDA 200 Independence Ave., S.W. Room 640-G Washington DC 2020 |
|
| November 1, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 31, 2018 SIGA TECHNOLOGIES, INC. |
|
| November 1, 2018 |
SIGA Announces Priority Review Voucher Transaction Totaling $80 Million Exhibit 99.1 SIGA Announces Priority Review Voucher Transaction Totaling $80 Million November 1, 2018, 7:30am ET NEW YORK - SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has entered into an agreement to sell its medical countermeasures priority review voucher (PRV) for a lump sum payment of $8 |
|
| November 1, 2018 |
Exhibit 2.1 EXECUTION VERSION Asset Purchase Agreement by and between SIGA Technologies, Inc. and Eli Lilly and Company October 31, 2018 Asset Purchase Agreement This Asset Purchase Agreement (this “Agreement”) is made and entered into as of October 31, 2018 (the “Effective Date”), by and between Eli Lilly and Company (“Buyer”) and SIGA Technologies, Inc. (“Seller”). Buyer and Seller may hereinaft |
